Lipella’s LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial and an FDA designation request in 2025.
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes
